Kellogg's is legally challenging new government rules limiting the prominence of sugary foods in English shops as part of a new campaign against obesity.
Chris Silcock, Kellogg's UK managing director, bemoaned that they had sought for the previous 12 months to have a constructive talk with the UK government about making this adjustment, but to no effect.
The UK government's strategy only calculated the fat, salt, and sugar content of cereals when eaten dry, not when taken with milk, according to Kellogg's.
The whole nutritional worth of a meal is not measured unless the nutritional ingredients are added when cereal is consumed with milk, according to Silcock.
To reduce children's exposure to unhealthy foods, the new regulations, which take effect in England in October, would prohibit television promotion of unhealthy foods before 9 p.m.
According to the state-funded National Health Service (NHS), 10% of four- and five-year-olds are fat, and the rate is double for those aged 10 and 11.
It goes on to say that one in every four persons is obese, blaming inexpensive, high-calorie foods in part.
The government said it would fight Kellogg's lawsuit, citing the fact that obesity costs the NHS more than $7.5 billion per year and is the UK's second leading cause of cancer.
Breakfast cereals account for 7% of children's average daily free sugar intake, which is a significant amount.
Limiting the marketing and advertising of less healthy foods is an important aspect of the cross-government strategy to reduce children's obesity by half by 2030, avoid hazardous diseases, and increase healthy life expectancy so that we may continue to improve health across the country.


RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Meta Faces Lawsuit Over Alleged Approval of AI Chatbots Allowing Sexual Interactions With Minors
Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
South Korea’s Weak Won Struggles as Retail Investors Pour Money Into U.S. Stocks
Dow Hits 50,000 as U.S. Stocks Stage Strong Rebound Amid AI Volatility
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
India–U.S. Interim Trade Pact Cuts Auto Tariffs but Leaves Tesla Out 



